These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 25320259

  • 1. Multiple sclerosis reactivation postfingolimod cessation: is it IRIS?
    Alroughani R, Almulla A, Lamdhade S, Thussu A.
    BMJ Case Rep; 2014 Oct 15; 2014():. PubMed ID: 25320259
    [Abstract] [Full Text] [Related]

  • 2. Fingolimod and multiple sclerosis: four cautionary tales.
    Bourdette D, Gilden D.
    Neurology; 2012 Nov 06; 79(19):1942-3. PubMed ID: 23035058
    [No Abstract] [Full Text] [Related]

  • 3. New disease-modifying therapies and new challenges for MS.
    Yadav V, Bourdette D.
    Curr Neurol Neurosci Rep; 2012 Oct 06; 12(5):489-91. PubMed ID: 22760478
    [Abstract] [Full Text] [Related]

  • 4. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
    Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, Ruet A, Debouverie M, Le Page E, Casez O, Heinzlef O, Stankoff B, Bourre B, Castelnovo G, Rico A, Berger E, Camdessanche JP, Defer G, Clavelou P, Al Khedr A, Zephir H, Fromont A, Papeix C, Brochet B, Pelletier J, Lebrun C, Club Francophone de la Sclérose en Plaques Investigators.
    JAMA Neurol; 2014 Apr 06; 71(4):436-41. PubMed ID: 24566807
    [Abstract] [Full Text] [Related]

  • 5. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C, Tintoré M, Aguilera C.
    Med Clin (Barc); 2012 Sep 22; 139(7):316-8. PubMed ID: 22743277
    [No Abstract] [Full Text] [Related]

  • 6. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N, Lahoz R, Reynolds T, Korn JR.
    Curr Med Res Opin; 2014 Aug 22; 30(8):1461-71. PubMed ID: 24754349
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Multiple sclerosis: closing in on an oral treatment.
    Martin R.
    Nature; 2010 Mar 18; 464(7287):360-2. PubMed ID: 20237554
    [No Abstract] [Full Text] [Related]

  • 9. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
    Havla J, Tackenberg B, Hellwig K, Meinl I, Krumbholz M, Seitz F, Eienbröker C, Gold R, Hohlfeld R, Kleiter I, Kümpfel T.
    J Neurol; 2013 May 18; 260(5):1382-7. PubMed ID: 23266894
    [Abstract] [Full Text] [Related]

  • 10. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis.
    Ward MD, Jones DE, Goldman MD.
    Expert Opin Drug Saf; 2014 Jul 18; 13(7):989-98. PubMed ID: 24935480
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis.
    Castillo-Trivino T, Lopetegui I, Alarcón-Duque JA, López de Munain A, Olascoaga J.
    J Neurol Neurosurg Psychiatry; 2015 Aug 18; 86(8):931-2. PubMed ID: 25835036
    [No Abstract] [Full Text] [Related]

  • 14. Multiple sclerosis: Natalizumab to fingolimod--the washout whitewash.
    Stangel M, Stüve O.
    Nat Rev Neurol; 2014 Jun 18; 10(6):311-3. PubMed ID: 24840971
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [A plan for risk management in the treatment of multiple sclerosis with gilenia (fingolimod)].
    Popova NF.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011 Jun 18; 111(2 Pt 2):110-3. PubMed ID: 21916166
    [No Abstract] [Full Text] [Related]

  • 17. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS.
    J Neurol Sci; 2011 Dec 18; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA, Chun J.
    Ann Neurol; 2011 May 18; 69(5):759-77. PubMed ID: 21520239
    [Abstract] [Full Text] [Related]

  • 19. New drugs may improve, complicate treatment for multiple sclerosis.
    Link H, Martin R.
    Nat Med; 2010 Mar 18; 16(3):272. PubMed ID: 20208513
    [No Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of natalizumab versus fingolimod for the treatment of relapsing multiple sclerosis.
    O'Day K, Meyer K, Miller RM, Agarwal S, Franklin M.
    J Med Econ; 2011 Mar 18; 14(5):617-27. PubMed ID: 21777161
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.